N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.

Roberto A Leon-FerreEdith A PerezDavid W HillmanCelyne BuenoAlejandra T PerezBeiyun ChenRobert B JenkinsDonald W NorthfeltDavid B JohnsonRobert L CarollaRobin T ZonAlvaro Moreno-Aspitia

Published in: Breast cancer research and treatment (2020)

TCHL was a tolerable regimen at a starting L dose of 750 mg PO daily when given concurrently with chemotherapy.

Keyphrases

positive breast cancer
phase ii study
early stage
locally advanced
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
epidermal growth factor receptor
sentinel lymph node
physical activity
metastatic breast cancer
study protocol
open label
randomized controlled trial
lymph node